Latest News and Press Releases
Want to stay updated on the latest news?
-
REDWOOD CITY, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
REDWOOD CITY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
-Company prioritizes its navicixizumab resources in platinum-resistant ovarian cancer; prepares to share data in Q4 of 2018- -Cash runway extended by an additional quarter to YE 2019- REDWOOD CITY,...
-
Expanded Phase of Trial will Assess anti-TIGIT in Combination with anti-PD1 REDWOOD CITY, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage...
-
Q1 Cash Balance of $88.4 Million—Cash through Q3 2019 First patient expected to be dosed in Phase 1b portion of anti-TIGIT trial in second quarter of 2018 Navicixizumab data expected in second half...
-
REDWOOD CITY, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer...
-
REDWOOD CITY, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
REDWOOD CITY, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
REDWOOD CITY, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
Navicixizumab and anti-TIGIT data expected in the 2nd Half of 2018 Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET / 1:30 p.m. PT REDWOOD CITY, Calif., March 08, 2018 ...